Concord Medical Services Holdings Limited (NYSE:CCM) Sees Significant Growth in Short Interest

Concord Medical Services Holdings Limited (NYSE:CCM) was the recipient of a significant growth in short interest during the month of May. As of May 15th, there was short interest totaling 7,483 shares, a growth of 134.9% from the April 30th total of 3,186 shares. Based on an average daily volume of 86,277 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.3% of the shares of the company are short sold.

Concord Medical Services Trading Up 2.1%

Shares of NYSE CCM traded up $0.11 during midday trading on Monday, reaching $5.04. 76,684 shares of the company traded hands, compared to its average volume of 62,888. The stock has a 50-day moving average price of $4.29 and a 200 day moving average price of $4.13. Concord Medical Services has a 52 week low of $3.18 and a 52 week high of $10.77. The company has a debt-to-equity ratio of 1.33, a current ratio of 0.48 and a quick ratio of 0.46.

Concord Medical Services (NYSE:CCM) last released its earnings results on Wednesday, April 29th. The company reported ($1.08) earnings per share (EPS) for the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Concord Medical Services in a research note on Tuesday, May 26th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell”.

Concord Medical Services Company Profile

Concord Medical Services Holdings Limited is one of China’s leading providers of radiotherapy equipment and oncology services. The company specializes in supplying and operating advanced radiotherapy machines, including linear accelerators, computed tomography (CT) simulators and brachytherapy units, to public and private hospitals. Through its integrated service model, Concord Medical Services delivers treatment planning, machine maintenance and clinical support to enhance the precision and effectiveness of cancer therapies.

Founded in 1997 and headquartered in Beijing, Concord Medical Services has developed an extensive network of oncology centers across major cities and provinces in China.